Literature DB >> 1590100

Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD.

M C Jia1, L Y Zhou, S Ren, L Dong, B Xiao.   

Abstract

Daily serum sex hormone binding globulin (SHBG) levels were measured during normal ovulatory menstrual cycles in ten women between the ages of 23 and 34 by the method of precipitation with ammonium sulfate. The results showed that the mean SHBG levels in a cycle were quite different among individuals, but that the SHBG levels were constant during a certain menstrual cycle. Neither SHBG peaks on day LH-0 (52.64 +/- 19.89 nmol/L) (x +/- SD) nor the mean SHBG levels between the follicular phase (57.10 +/- 17.64 nmol/L) and luteal phase (64.75 +/- 23.42 nmol/L) show any significant differences. The correlations between the mean SHBG levels and the mean concentrations of progesterone (P), estradiol (E2) and androstenedione during the menstrual cycles were insignificant, whereas the mean SHBG levels during the follicular and luteal phase and on LH-0 day were significantly correlated with the mean concentrations of testosterone (t = 0.474; p less than 0.05). In ten women between the ages of 25 and 34, serum SHBG, E2, P, and levonorgestrel (LNG) levels were measured once on day 20-21 of the pretreatment cycle and 3 times/week during the 1st, and 2 times/week during the 6th treatment cycle after insertion of a levonorgestrel-releasing IUD (LNG-IUD). The mean value of SHBG in the pretreatment blood samples (62.09 +/- 23.09 nmol/L) was higher than that after insertion of the LNG-IUD (41.82 +/- 20.50 nmol/L), though the difference was not significant (p greater than 0.05). The correlation between LNG and SHBG was highly significant (r = 0.89, p less than 0.01). The significance of this correlation and the degree of suppression of ovarian function are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590100     DOI: 10.1007/bf01849346

Source DB:  PubMed          Journal:  Adv Contracept        ISSN: 0267-4874


  5 in total

1.  Risk of intracranial hypertension with intrauterine levonorgestrel.

Authors:  Mahyar Etminan; Hao Luo; Paul Gustafson
Journal:  Ther Adv Drug Saf       Date:  2015-06

Review 2.  A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.

Authors:  F Sturridge; J Guillebaud
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

3.  Benefit-risk assessment of the levonorgestrel intrauterine system in contraception.

Authors:  Tiina Backman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Estradiol Binds to Insulin and Insulin Receptor Decreasing Insulin Binding in vitro.

Authors:  Robert Root-Bernstein; Abigail Podufaly; Patrick F Dillon
Journal:  Front Endocrinol (Lausanne)       Date:  2014-07-21       Impact factor: 5.555

5.  Relationship between de novo lipogenesis and serum sex hormone binding globulin in humans.

Authors:  Pomme I H G Simons; Olivier Valkenburg; Ine Telgenkamp; Koen M van der Waaij; David M de Groot; Pandichelvam Veeraiah; Judith A P Bons; Marja-Riitta Taskinen; Jan Borén; Patrick Schrauwen; Joost H W Rutten; David Cassiman; Casper G Schalkwijk; Coen D A Stehouwer; Vera B Schrauwen-Hinderling; Leanne Hodson; Martijn C G J Brouwers
Journal:  Clin Endocrinol (Oxf)       Date:  2021-03-28       Impact factor: 3.478

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.